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Volume 57, Number 5S Abstracts 87Sincluding endoleak, aneurysm sac growth, and any surgical
or endovascular intervention. Thirteen patients who had no
postoperative contrast-enhanced CT scans were excluded.
Our practice has been to obtain CTA’s at postoperative
months 1, 6, and 12 and then yearly for 5 years.
Results: The mean patient follow up was 3.4 6 2
years. Of 91 patients, 71 (78%) had a normal CTA at 1
month after EVAR without endoleak or other abnormality.
Four of these 71 (5.6%) developed late complications con-
sisting of three type II endoleaks and one type I endoleak,
which presented on postoperative days 240, 1135, 1383,
and 1294, respectively. Only one of the type II endoleaks
was accompanied by aneurysm sac growth requiring repair
and the small type I endoleak was also repaired.
Conclusions: For patients who have a normal CTA
with no endoleak one month after EVAR it is reasonable
to consider less frequent CTA surveillance as no signiﬁcant
complications requiring intervention occurred before three
years.
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1EmoryUniversity, Atlanta,Ga; 2AtlantaVAMC,Atlanta,GaFig.Objectives: Despite optimal medical therapy of
uncomplicated Type B aortic dissections (TBAD), true
lumen narrowing and aneurysmal degeneration of the false
lumen can occur over the long-term (>6 months). The
efﬁcacy of thoracic stent-grafts (TEVAR) for aortic remod-
eling when placed at late time points remains controversial.
We studied post-TEVAR aortic volumetric changes in
these patients.
Methods: Utilizing tomographic scans, volumes of
multiple aortic compartments were calculated including
the stented true lumen (STL), peri-stented false lumen
(SFL), true lumen from distal stent to celiac axis (infra stent
true lumen, ISTL), and the corresponding false lumen
(ISFL). Cross-sectional areas were calculated at one centi-
meter intervals, collated, and volumetric ratios were
derived from preoperative values.
Results: From 2004-2011, twenty-one patients met
inclusion criteria. The time from index dissection to
TEVAR was 197 days or greater. The left subclavian artery
was covered in 71.4% of cases. Best-ﬁt line statistical regres-
sion analysis of volumetric change demonstrated increases
in ISTL and total TL volumes by 55% and 38%, respec-
tively (P < .05) at one year (Fig, A and B). SFL and
ISFL volumes decreased by 41% and 32%, respectively (P <
.05) (Fig, C and D).
Conclusions: TEVAR for aneurysmal degeneration
after long-term medical therapy of TBAD results in volu-
metric gain of the true lumen and false lumen regression.
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Objectives: Patients undergoing EVAR of AAA can
exhibit variations in sac behavior from complete regression
to expansion. We evaluated the impact of sac behavior at
one year follow up on late survival.
Methods: We used the Vascular Study Group of New
England (VSGNE) registry (2003-2011), to identify
EVAR patients with one year CT follow up. Aneurysm
sac enlargement >5 mm (SacEn) or decrease >5 mm
(SacDe) was deﬁned according to SVS guidelines and
predictors of change in sac size and impact of sac behavior
were assessed by multivariable methods.
Results: 1642 EVAR patients with one year follow up
were included. At 1 yr, 8% had SacIn, 72% had SacDe, and
20% had stable sac size. Independent predictors of SacIn
were urgent repair (OR, 2.9; 95% CI, 1.7-5.0; P < .01),
intraoperative type I/III endoleak (OR, 2.7; 95% CI,
1.1-6.9; P ¼ .03), hypogastric coverage (OR, 2.2; 95%
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95% CI, 1.1-2.6; P < .01). SacDe was more likely to occur
in smokers (OR, 1.7; 95% CI, 1.2-2.4; P < .01), and less
likely to occur in patients who had iliac aneurysm repair
(OR, 0.7; 95% CI, 0.5-0.95; P ¼ .02), and any re-interven-
tion (OR, 0.6; 95% CI, 0.4-0.9; P ¼ .03). Risk adjusted
(age, symptoms/rupture, reintervention, hypogastric
coverage, low EF, smoking) Cox regression showed that
SacIn independently predicted increase in late mortality
(HR, 2.2; 95% CI, 1.4-3.7; P < .01), while SacDe had
no impact (HR, 0.9; 95% CI, 0.6-1.3; P ¼ .5). Long-
term survival was lower (log-rank, P < .01) in patients
with SacIn (94 6 2% 1 yr and 57 6 6% 5 yr) compared
to all others (99 6 1% 1 yr and 81 6 2% 5 yr).
Conclusions: These data suggest that AAA sac size
increase greater than 5 mm at one year, albeit infrequent
is an independent predictor of late mortality and warrants
close observation and early intervention.
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Objectives: Total arch repair (TAR) is the gold stan-
dard therapy for arch aneurysm, however, there is room
for improvements. We present the outcome of our endo-
vascular strategy for arch aneurysms.
Methods: During the last 3 years, we performed
Chimney technique (38 cases) and the Retrograde In-situ
Branched Stent grafting (RIBS, seven cases) to treat 45
patients with arch aneurysms all of whom were considered
to be at high risk for TAR. The chimney technique involves
a uni or bi-lateral common carotid artery exposure and inser-
tionof a small diameter covered stent to preserve cerebralﬂow
in conjunction with the deployment of the main endograft in
the ascending aorta. The RIBS method was developed in an
aim to reduce gutter endoleak associated with the Chimney
technique. The RIBS procedure is performed by puncturing
the main endograft in a retrograde manner and followed by
balloon dilatation and covered stent deployment.
Results: The mean aneurysm diameter (short axis) was
6.6 cm. The overall OR time was 318 6 126 minutes and
blood loss was 703 6 730 mL and 12 (26%) patients
required blood transfusion. Endoleak was encountered in
three (7.9%) cases and all were among the Chimney
patients as a result of gutter EL. There were no cases
with endoleak among the RIBS patients. There was one
mortality (2.2 %) that resulted from intraoperative retro-
grade type A dissection. Stroke occurred in one case
(2.2%) but it was minor and resolved completely.
Combined stroke death rate was 4.4%. During a mean
FU of 11.266.9 months, no aneurysm rupture has been
encountered.Conclusions: Both the Chimney technique and the
RIBS procedure are safe and effective and can be consid-
ered as an alternative option for those patients unﬁt for
TAR. RIBS appear to be advantageous in further elimi-
nating gutter endoleak.
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Objectives: During EVAR for ruptured AAA (r-AAA)
inadequate aortic neck morphology often requires
surgeons to expand the stent graft ‘indications for use’
(IFU). This is the ﬁrst study to date that evaluates
outcomes of patients with r-AAA that underwent EVAR
with favorable aortic neck (f-AN) vs hostile aortic neck
(h-AN), vs open surgical repair (OSR).
Methods: Over a 5-year period, 180 patients with
r-AAA underwent EVAR (n ¼ 74; 41.1%) or OSR (n ¼
106; 58.9%). The 74 r-EVAR patients were divided into
2 groups based on f-AN (n ¼ 25; 33.7%) vs h-AN (n ¼
49; 66.7%) morphology. Data was collected prospectively,
and aortic neck measurements were standardized relative to
the IFUs of particular stent graft. Patients were analyzed on
an intention-to-treat basis and outcomes were evaluated by
logistic regression multivariable analysis.
Results: The 30-daymortalitywas the lowest in r-EVAR
patientswith f-ANand the highest in theOSRpatients (f-AN,
8%; h-AN, 23%;OSR, 43.4%; P< .01), and both f-AN and h-
AN r-EVAR patients had a better cumulative 3-year survival
than OSR (f-AN, 64%; h-AN, 67%; OSR, 44%; P < .01).
The r-EVAR patients with h-AN had a signiﬁcantly higher
incidence of female gender (32% vs 19%; P < .05), mean
maximum AAA diameter (7.4 cm vs 5.5 cm; P < .05),
abdominal compartment syndrome (ACS) (20% vs 4%; P <
.05), Type I endoleaks (16% vs 4%; P < .05), and the need
for all secondary interventions (77% vs 40%; P < .05).
Conclusions: For r-AAA, although EVAR provides the
greatest beneﬁt to patients with f-AN, even patients with
h-AN experience a survival beneﬁt at 3 years when com-
pared to OSR. However, r-EVAR patients with h-AN expe-
rience a higher incidence of ACS, Type I endoleaks, and
secondary interventions, and mandate vigilant follow-up.
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